GAMIFANT 50 mg/2mL
emapalumab-lzsg · INJECTION · Swedish Orphan Biovitrum AB (publ)
Gamifant is an intravenous injection used to treat primary hemophagocytic lymphohistiocytosis, a rare inherited immune disorder where the immune system becomes overactive and damages the body's organs and tissues. It works by blocking interferon gamma, a protein that drives this harmful immune response.
Key Facts
- Brand Name
- GAMIFANT
- Generic Name
- emapalumab-lzsg
- NDC Code (Product)
66658-522- Manufacturer
- Swedish Orphan Biovitrum AB (publ)
- Strength
- 50 mg/2mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761107
- Drug Class
- Interferon gamma Blocker [EPC]
- Marketing Start
- 06/07/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is GAMIFANT used for?
Gamifant is an intravenous injection used to treat primary hemophagocytic lymphohistiocytosis, a rare inherited immune disorder where the immune system becomes overactive and damages the body's organs and tissues. It works by blocking interferon gamma, a protein that drives this harmful immune response.
Is GAMIFANT a controlled substance?
GAMIFANT is not classified as a controlled substance by the DEA.
What is the generic name for GAMIFANT?
The generic name for GAMIFANT is emapalumab-lzsg. There are no other listed brand versions of emapalumab-lzsg.
What is the NDC code for GAMIFANT 50 mg/2mL?
The NDC (National Drug Code) for GAMIFANT 50 mg/2mL is 66658-522, listed by Swedish Orphan Biovitrum AB (publ).
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)